The global glioblastoma multiforme (GBM) treatment market is driven by the high incidence and prevalence of this aggressive brain tumor. GBM is one of the most common and deadly types of primary brain cancer, with an estimated annual incidence rate of 3-4 cases per 100,000 people worldwide. In the U.S., approximately 12,000 new cases of GBM are diagnosed each year, with a median survival time of only 15-18 months after diagnosis. The increasing focus on early detection and the development of novel therapies, such as immunotherapies and targeted treatments, is contributing to advancements in the market. Additionally, the rising number of clinical trials and research into combination therapies and personalized medicine are expected to enhance treatment options and improve patient outcomes. As the global population ages, the prevalence of GBM is anticipated to rise, further influencing market dynamics and the demand for innovative treatment strategies.
